RCT 2023
Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical
Trial
Michael X. Repka;
Katherine K. Weise;
Danielle L. Chandler; Rui Wu;
B. Michele Melia; Ruth E. Manny;
Lori Ann F. Kehler;
Catherine O. Jordan;
Aparna Raghuram;
Allison I. Summers;
Katherine A. Lee;
David B. Petersen;
S. A. Erzurum; Yi Pang;
Phoebe D. Lenhart;
Benjamin H. Ticho; Roy W. Beck;
Raymond T. Kraker;
Jonathan M. Holmes;
Susan A. Cotter; ;
Denise D. Alexopoulous;
Megan Allen;
Heather A. Anderson;
Darrell S. Austin;
Shane C. Black; Nicole M. Boyle;
Grant Andrew Casey;
Moriah Adine Chandler;
Ryan Chinn; Deborah A. Clausius;
Beth J, Colon;
Courtney L. Conner;
Linda T. Curtis; Zainab Dinani;
Quayleen Donahue;
Michelle Dubois;
Patricia L. Evans;
Brooke P. Fimbel;
Melanie Kay Fowler;
Richard P. Golden;
Beth G. Harper;
Robert J. Henderson;
Dieu-Hong Ho; James E. Hoepner;
Kristine B. Hopkins;
Ashli S. Jenks;
Joseph D. Kaplon; Shabana Khan;
Cassandra A. Koutnik;
Annie F. Kuo; Jessy Lee;
Muriel M. Martinez;
Sophia M. Marusic;
Mary Lou McGregor;
J. Ryan McMurtrey;
Kathryn B. Miller;
Preeti L. Mokka;
Jenifer Montejo;
Beth A. Morrell; Elyse Nylin;
Kimberly C. Odom;
Gillaine Ortiz;
Samantha A. Parra;
Kyle J. Perkins; Larry W. Plum;
Ellen Fiona Redenbo;
Julianne L. Robinson;
Kathleen M. Stutz;
Desirae R. Sutherland;
Mircea X. Teodorescu;
Lori L. Torgensen;
David O. Toro;
Phillip B. Turner;
Natalie C. Weil;
Emily K. Wiecek;
Carsyn S. Wilkins;
Victoria C. Woodard;
Kevin M. Woodruff; Huizi Yin;
Marika L. Yumang;
Tomohiko Yamada; Noha S. Ekdawi;
David A. Leske;
David K. Wallace;
Melanie L. Christian;
Stephen R. Glaser;
Eileen E. Birch; Angela M. Chen;
Stephen P. Christiansen;
Laura B. Enyedi;
Donald F. Everett;
Sharon F. Freedman;
William V. Good;
Erin C. Jenewein;
Richard London; Vivian M. Manh;
David G. Morrison;
Stacy L. Pineles;
Hantamalala Ralay Ranaivo;
Tawna L. Roberts;
Scott T. Ruark;
Bonita R. Schweinler;
Jayne L. Silver; Donny W. Suh;
Lisa C. Verderber;
Marie Diener-West;
John D. Baker; Barry Davis;
Rosemary D. Higgins;
Stephen W. Poff;
Richard A. Saunders;
Lawrence Tychsen
JAMA ophthalmology
What does this source bring?
In the American PEDIG RCT, atropine 0,01% did not slow progression or axis prolongation relative to placebo.
The result relates to the tested concentration, preparation and population. It does not disprove the effects of all concentrations of atropine.
CLAIM-PEDIG
Scope of testing and verification
- The role of the record
- Source of the claim
- Population
- 5–12 children with myopia in the USA
- N
- 187
- Geography
- USA
- Observation (months)
- 24
- Comparator
- Placebo
- Result
-
In the American PEDIG RCT, atropine 0,01% did not slow progression or axis prolongation relative to placebo.
- Safety
- This record does not allow estimation of the frequency of rare adverse events.
- Device/structure
- Not applicable / not determined within the verified range
- Publisher of the publication
- American Medical Association (AMA)
- Financing
- Not determined within the proven range; see the declaration in full text.
- Conflicts of interest
-
Not determined within the proven range. The absence of confirmation does not mean the absence of conflict.
- DOI
- 10.1001/jamaophthalmol.2023.2855
- PMID
- 37440213
- What was checked
- Bibliographic metadata and abstract in Europe PMC / PubMed; Crossref metadata
- Date of verification
- 2026-09-09
This is the editorial card of the publication. The description does not replace the full text, supplementary data or instructions for a specific device.
